Olivia Brayer Analyst PerformanceAnalyst at Cantor FitzgeraldOlivia Brayer is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 10 publicly traded companies. Over the past year, Olivia Brayer has issued 14 stock ratings, including buy and hold recommendations. While full access to Olivia Brayer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Olivia Brayer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings19 Last 1 YearsBuy Recommendations89.47% 17 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution19RatingsDistribution of strong buy, buy, hold, and sell ratings by Olivia Brayer.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.5%17 ratings Hold10.5%2 ratings Sell0.0%0 ratingsOut of 19 total stock ratings issued by Olivia Brayer at Cantor Fitzgerald, the majority (89.5%) have been Buy recommendations, followed by 10.5% Hold.Best & Worst CallsBest Call00.0%VRTXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%BMRNFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ90.0% of companies on NASDAQ9 companiesNYSE10.0% of companies on NYSE1 companyOlivia Brayer, an analyst at Cantor Fitzgerald, currently covers 10 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical9 companies90.0%Manufacturing1 company10.0%Olivia Brayer of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE8 companies80.0%MED - DRUGS1 company10.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company10.0% Olivia Brayer's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsGOSSGossamer Bio3/23/2026Reiterated Rating$0.42Neutral$0.0000.00% ROIUTHRUnited Therapeutics3/12/2026Boost Price Target$535.20$625.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics2/4/2026Boost Price Target$5.78$10.00Overweight$0.0000.00% ROIVNDAVanda Pharmaceuticals12/17/2025Reiterated Rating$6.93Overweight$0.0000.00% ROIINSMInsmed12/16/2025Boost Price Target$196.92$230.00Overweight$0.0000.00% ROIIKTInhibikase Therapeutics12/11/2025Initiated Coverage$1.48$4.00Overweight$0.0000.00% ROIVNDAVanda Pharmaceuticals10/30/2025Lower Price Target$4.51$11.00Overweight$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share10/8/2025Reiterated Rating$106.95$100.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics9/22/2025Initiated Coverage$1.98$6.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics9/22/2025Initiated Coverage$2.06$6.00Overweight$0.0000.00% ROIGOSSGossamer Bio9/11/2025Reiterated Rating$3.11Overweight$0.0000.00% ROIUTHRUnited Therapeutics9/10/2025Boost Price Target$403.80$525.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics6/2/2025Initiated Coverage$316.34$405.00Overweight$0.0000.00% ROIVNDAVanda Pharmaceuticals5/14/2025Reiterated Rating$3.92$13.00Overweight$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/20/2025Reiterated Rating$68.49$90.00Overweight$00.0000.00% ROIVRTXVertex Pharmaceuticals2/11/2025Reiterated Rating$460.76$480.00Overweight$000.0000.00% ROIBMYBristol Myers Squibb2/4/2025Boost Price Target$60.03$55.00Neutral$00.0000.00% ROIVRTXVertex Pharmaceuticals1/31/2025Reiterated Rating$462.91$480.00Overweight$000.0000.00% ROIVRTXVertex Pharmaceuticals1/24/2025Reiterated Rating$439.97$480.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
